©2025 Stanford Medicine
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Recruiting
I'm InterestedTrial ID: NCT05041309
Purpose
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
Official Title
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Stanford Investigator(s)
David Miklos
James and Katherine Lau Professor
Saurabh Dahiya
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Inclusion Criteria:
* The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
* The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
* In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation
Exclusion Criteria: none
Intervention(s):
biological: Axicabtagene Ciloleucel
biological: Brexucabtagene Autoleucel
biological: KITE-363
biological: Anitocabtagene autleucel
biological: KITE-753
biological: KITE-197
biological: INT2104
biological: KITE-512
biological: SPRX001
biological: SPRX002
biological: ARC-T Cells
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130